ANO1 and prostate carcinoma: Research has demonstrated that inhibiting TMEM16A can hinder the proliferation and migration of cancer cells, indicating that new therapeutic strategies focused on reducing TMEM16A expression could aid in the treatment of prostate cancer [5].